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The high and increasing prevalence of Dry Eye Disease (DED) highlights the 
need for new treatment treatments and more effective management strategies for 
this chronic disease. After training, lid grooming, and various ocular lubricants, 
the Tear Film & Ocular Surface Society Dry Eye Workshop II (TFOS DEWS 
II) Management and Therapy Subcommittee recently proposed Intense Pulsed 
Light (IPL) as the second phase of therapy. Brief flashes of non-coherent light 
(400–1,200 nm) are delivered to the skin’s surface using IPL technology. Toyos et 
al. found in 2005 that rosacea sufferers who were treated with IPL in the periocular 
region had a significant increase in their dry eye symptoms.
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1. Introduction
The lipid layer of the tear film is deficient when the activity of the meibomian 
glands is impaired, which protects the aqueous layer of the tear film and prevents it 
from evaporating. The cornea is exposed as the tear film is destabilized, which leads 
to the onset of DED symptoms [1]. Since facial rosacea is closely linked to Meibomian 
Gland Dysfunction (MGD) and blepharitis [1], the IPL intervention of rosacea may 
have removed pathological telangiectasia periocular area, eliminating a significant 
source of inflammation to the eyelids and, as a result, alleviating MGD and dry eye 
problems. Since Toyos’ original publication, a slew of surveys and two Randomized 
Controlled Trials (RCT) [1, 2] have added to the body of evidence demonstrating the 
effectiveness (and safety) of IPL therapy for patients with DED caused by MGD [3]. 
Most of these studies showed that symptoms and a wide range of DED/MGD signals 
enhanced in these patients, such as Tear Breakup Time (TBUT), Non-Invasive Breakup 
Time (NIBUT), Schirmer examination, presence of phEx™. Tear inflammatory mark-
ers, lipid layer grade, lipid layer thickness, Corneal Fluorescein Staining (CFS), meibum 
consistency, meibum expressibility, and lid margin anomalies were investigated.
2. Definition and history of DED
Dry Eye Syndrome or Disease (DES or DED) is a chronic Ocular Surface Disease 
(OSD) that influences vision and, consequently, quality of life similar to angina 
pectoris.
The prevalence of DE varies by region and population, ranging from 5–50% and 
up to 75%. Female gender, Age, excessive cold or hot weather, low relative humidity, 
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proximity to video monitor terminals, contact lens wear, history of refractive 
surgery, smoking, and prescriptions are some risk factors [4–13].
Geographical area, research demographic differences, and a lack of consistent 
diagnosis criteria are thought to cause the significant disparity of prevalence 
worldwide (Figure 1) [13].
3. Diagnose of DED
There is not a gold standard for diagnosing dry eye disease. However, evalua-
tions can arise from the following methods:
3.1 Standard patient evaluation of eye dryness (SPEED) questionnaire
This validated questionnaire [1, 14] asked the subject to grade the frequency and 
severity of four symptoms categories: (1) dryness, grittiness, or scratchiness; (2) 
soreness or irritation; (3) burning or watering; and (4) eye fatigue. For each of these 
symptom categories, the subject subs-cored the frequency using a 4-point scale  
(0 = never, 1 = sometimes, 2 = often, 3 = constant), and sub-scored the severity 
using a 5-point scale (0 = none, 1 = tolerable, 2 = uncomfortable, 3 = bothersome,  
4 = intolerable). The SPEED score was calculated as the sum of these eight 
sub-scores. A SPEED score ≥ of 10 is widely accepted as indicating severe DED 
symptoms, 12. A cut-off value around six is often used to distinguish between 
asymptomatic/mild and moderate/severe symptoms.
3.2 Corneal fluorescein staining (CFS)
Assessment of corneal staining was evaluated as follow: [15]. Immediately 
following TBUT measurement and taking advantage of the residual staining in the 
ocular surface, the examiner observed four anatomical quadrants of the cornea 
(temporal superior, temporal inferior, nasal superior, nasal inferior) under the slit-
lamp. Each quadrant was sub-scored using a 4-point scale; 0: no staining, 1: 1–30 
instances of punctate staining, 2: 30 instances of punctate staining, without infused 
lesions or ulcers, or 3: the existence of infused lesions or ulcers. The sum of these 
Figure 1. 
Timeline diagram: IPL for DED treatment; ↑: Improvement, OSDI: Ocular surface disease index, BUT: Break 
up time, SPEED: Standard patient evaluation of eye dryness questionnaire.
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four sub-scores, ranging from 0 to 12, defined the CFS score. The CFS score was 
evaluated at baseline (BL) and follow-up (FU).
3.3 Composite eyelid score (CES) and change of compound eyelid score (CCES)
A Composite Eyelid Score (CES) was compounded based on the presence or 
absence of five abnormal anatomical features of the eyelids: (1) hyperemia of 
anterior lid margin; (2) thicken lid margin; (3) rounded lid margin; (4) hyper-kera-
tinization of the lid margin; and (5) telangiectasia around meibomian gland orifices.
These five features were evaluated at BL and FU. Each one was sub-scored 1 if 
the abnormality was present, or 0 otherwise. In the analysis, CES was calculated as 
the sum of these five sub-scores, thus ranging from 0 (all five features absent) to 5 
(all five features present). At FU, the examiner used photos of the eyelids captured 
at BL to determine whether there was an improvement (+1), no change (0), or a 
deterioration (21) for each of these features. The sum of these five sub-scores, rang-
ing from 25 (if all five features deteriorated) to +5 (if all five features improved), 
was defined as the Change in CES (CCES).
3.4 Tear breakup time (TBUT)
The diagnosis subcommittee on the International Workshop on MGD proposed 
that TBUT ranges of 1 to 3 sec, 3 to 5 sec, and 5 to 7 sec indicate moderate, mild, and 
minimal severity levels, respectively.
3.5 Ocular surface disease index (OSDI)
OSDI (Allergan, Inc., Irvine, CA) is a frequently used instrument to assess DE 
and provides a quantifiable assessment of DE symptom frequency and the impact 
of these symptoms on vision-related functioning. It contains 12 items, and the score 
can range from 0 (no symptoms) to 100 (severe symptoms) points; 0 to 12 repre-
sents normal, 13 to 22 represents mild DED, 23 to 32 represents moderate DED, and 
greater than 33 represents severe DED.
3.6 Tear film lipid layer (TFLL) quality by TFLL interferometry
Noninvasive TFLL quality assessment was performed with DR-1 (Kowa, Nagoya, 
Japan). Yokoi DE severity grading system was performed. Grade 1: somewhat gray 
color, uniform distribution; grade 2: rather gray color, nonuniform distribution; 
grade 3: a few colors, nonuniform distribution; grade 4: many colors, nonuniform 
distribution; and grade 5: corneal surface partially. 24 of refractive, refractive.
3.7 Meibum gland (MG)
The quality of the meibum was assessed by expressing the meibomian glands 
with the Meibomian Gland Evaluator (MGE; Tear Science, Inc., Morrisville, NC), a 
standardized instrument developed by Korb et al., and then evaluating the quality 
of meibomian secretions [16]. MGE was applied for 15 glands (5 nasal+5 central+5 
temporals) along the lower eyelid. For each gland, the examiner sub-scored the 
quality of the expressed meibum using a four-point scale: 0 (no secretion), 1 
(inspissated or toothpaste-like secretion), 2 (cloudy liquid secretion), or 3 (clear 
liquid secretion). The sum of this 15 subs-cores, ranging from 0 to 45, defined the 
Meibomian Gland Yielding Secretion Score (MGYSS). MGYSS was evaluated at BL 
and FU [1].
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4. Enhanced management and treatment for dry eye (DE)
The 2017 TFOS DEWS II provides guidelines for a stepped treatment protocol 
for DE, which targets each abnormality in the Tear Film-Oriented Diagnosis 
(TFOD) approach (Figure 2) [17–19].
4.1 Drug therapy
The inflammation, along with dry eye usually treats with topical corticosteroids. 
In cases with little satisfaction, a second-line drug is Topical cyclosporine A [20].
Lifitegrast 5% is a second topical anti-inflammatory ocular drop that got FDA 
approved In July 2016 for DED.
Other drugs include lipid-containing eye drop, artificial tear formulations with 
nanostructured lipid carriers as a synthetic TF in vivo, and castor oil emulsions 
are promising as Preservative-free drops, omega-3 fatty acid, supplementation, 
serum tears, topical azithromycin, oral and topical HA oral doxycycline, topical 3% 
Diquafosol and cholinergic.
4.2 Procedures
Intense pulse light, lacrimal plug, lid massage and probing and expression of 
MG, warm compresses or vectored thermal pulsation, and amniotic membrane bio-
logic corneal bandage lens have evolved to improve the signs and symptoms of DE.
5. Definition of IPL
An intense pulsed light (IPL) system is a non-laser large source of light that 
produces a non-coherent light output of broad wavelength, usually in the range of 
500 to 1200 nm, using a high-performance flashbulb. Many modern tools create 
light pulses by transmitting bursts of electricity running through a xenon gas-filled 
chamber [21–23].
The usage of IPL in medicine is based on the fact that unique load transfer 
targets (chromophores) can absorb photons from a wide range of light wavelengths 
(absorptive band) without being specifically targeted by their highest absorption. 
Figure 2. 
Step-up treatment for DED.
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The IPL uses targeted photo thermolysis, in which thermally induced radiation harm 
is restricted to the selected epidermis and dermis textured targets at the cellular or 
tissue structural difference [24]. Toyos et al. reported improvements in MGD associ-
ated Dry Eye Disease (DED) cases in 2002 and was the first published report on 
using an IPL system in ophthalmology [25, 26]. IPL dilates the capillaries and causes 
them to involute using electromagnetic waves of specific wavelengths [27]. This 
causes the leaked inflammatory responses to be suppressed, interrupting the vicious 
cycle of inflammation and enhancing dry eye signs. In most cases, it also functions 
with the aid of thermal pulsation [28]. When chronic inflammation occurs, the 
structure of the meibum improves to contain many monounsaturated fats. Those 
fats have a melting point of close to 45°C, which is greater than body temp [29]. This 
meibum does not melt through the lipid coating of the tear film as it should, clogging 
the glands. Thermal pulsation treatment liquefies the meibum and clears the glands 
by combining continuous pressure and heat. Traditional manual expressing glands 
is ineffective, inconvenient for patients, and could result in scarring [29]. Thermal 
pulsation is an effective and safe treatment option. With these processes in mind, we 
have deduced that IPL will help alleviate the symptoms of DE [21, 30].
6. Causes of dry eye and applications of IPL
The surface epithelial and glandular tissues (cornea, bulbar and palpebral con-
junctiva, lacrimal and accessory eyelid), the glycocalyx, and the tear film consist of 
the microenvironment of the ocular surface [31].
Systemic disorders such as rheumatoid arthritis, Sjogren’s syndrome, thyroid eye 
disease, sleep apnea [32], cicatrizing disease of the conjunctiva, contact lens wear, 
and refractive laser surgery are the most underlying associated conditions with 
Refractory DE. DE signs after Laser-Assisted in Situ Keratomileuses (LASIK) are 
not standardized. There is a continuum of disorders such as neurotrophic disease, 
tear film dysfunction, aqueous tear deficiency, and neuropathic pain conditions. 
Cutting the corneal nerves during Laser ablation and creating the flap are probable 
reasons for post-refractive DE. Meibomian glands are adjusted sebaceous glands 
located inside the lower and upper eyelids, with ducts terminating along the eyelid 
borders and secreting meibum, contributing directly to the lipid portion [31, 33].
The Tear Film Lipid Layer (TFLL) leads to the tear film’s consistency and 
stabilization. The presence of TFLL on the tear film’s exterior layer decreases the 
tear film’s evaporation.
Negative TFLL changes may trigger evaporative DE, as well as symptomatic and 
clinical ocular surface manifestations [34]. Inflammation and illness TFLL were 
shown to be slightly lower in post-LASIK eyes, along with worsening DE symptoms 
and reduced corneal sensitivity [35].
A previous study reported the improvement of refractory DE with polar and 
nonpolar lipid base, ofloxacin eye ointment [36]. Another study reported the corre-
lation between the severity of DE with lipid layer thickness secondary to increased 
evaporation as the most common etiologies for increased osmolarity of the tear 
film [37].
Scanning electron microscopy showed that lipids expressed by the meibomian 
gland caused extensive damage to gram-positive and gram-negative bacteria and 
hence acts as a protective barrier against pathogens [38]. Thus, improvement of the 
TFLL maintains the homeostatic balance by protecting the ocular surface environ-
ment. Therefore, the progress of symptoms and reduction of artificial tears after 
refractive surgery is another positive report about IPL treatment. However, future 
study elucidates the duration and the optimal dose [39, 40].
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7. Mechanisms of IPL for prevention of damage to the ocular surface
A better explanation of the mechanisms of IPL leads to a better treatment plan. 
Regarding several mechanisms, it would be nice to describe as follow:
Demodex folliculorum and Bacillus oleronius are common inhabitants of 
human hair follicles and sebaceous glands occasionally found in ocular rosacea. 
IPL increases mitochondrial activity and wound healing, decreasing lid marginal 
bacteria and Demodex by photocoagulation, improving elastosis, and connective 
tissue disorganization that occurs with MGD rosacea to relieve pain (Figure 3).
7.1 Effects on mucin and corneal nerve
Mucin plays many essential roles on the ocular surface, including maintaining 
lacrimal fluid, lubricating the ocular surface to facilitate flat blinking, forming a 
smooth spherical surface for clear vision, providing an ocular surface shield and 
trapping and eliminating contaminants and debris [41–43]. The tear film is divided 
into two layers, with the aqueous layer containing secreted mucin MUC5AC scat-
tered across [42]. Xue et al. discovered no improvements in MU5AC expression 
after IPL procedures Utilizing conjunctival impression cytology,. IPL therapy has 
little effect on the density of nerve fibers and dendritic cells in the corneal sub-basal 
layer, according to research [44].
7.2  Pro- and anti-inflammatory molecule effects, as well as matrix 
metalloproteinase suppression
Factors that influence tear film stability and osmolarity can cause ocular injury 
and trigger an inflammatory cascade that leads to a strong immunological reaction, 
leading to further ocular surface injury, causing a self-perpetuating inflamma-
tory loop [45]. By upregulating anti-inflammatory cytokines, downregulating 
proinflammatory cytokines, or both, IPL can disrupt the inflammatory cycle. Dry 
eye’s inflammatory cascade is highly complex and little known. Nevertheless, at 
least part of IPL’s positive effect on DED patients may come from messing with the 
pathology’s inflammatory cycle’s positive feedback loop [46]. Interference with 
the inflammatory process by modulating anti-inflammatory factors and Matrix 
Metalloproteinase (MMP), lowering the turnover of skin epithelial cells, reducing 
the rate of severe obstruction of the meibomian glands, and improving the levels of 
active oxidative species all aid in the prevention of dry eye symptoms.
Figure 3. 
IPL treats MGD; IHMGEC: Immortalized human MG epithelial cells; SREBP-1: Sterol regulatory element-
binding protein 1.
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8. Adverse events and advantages
There were no adverse effects with the IPL. Nevertheless, the relationship 
between Intense Pulsed Light (IPL) and Meibomian Gland Expression (MGX), or 
Warm Compresses (WC) and MGX, on the one hand, and MGX on the other hand, 
maybe non-linear and complex. Since IPL can be expensive in some clinics, it’s 
essential to know if persistent eyelid warmth at home accompanied by WC/MGX 
can produce comparable results as IPL/MGX. However, Broadband Light (BBL) 
technology has the potential to cause damage. Just transient side changes were 
reported, such as hyperpigmentation, eyelash thinning, and slight conjunctival 
abrasion. The lid thinning has been seen by using higher settings than those pre-
scribed in this report, and the suspected abrasion was most likely caused by slight 
damage caused by the corneal shields in the close eyelids’ environment, rather than 
the BBL therapy itself. Other warnings that can help to reduce the low risk of tran-
sient lash thinning include scraping any gel that may couple with the light from the 
lashes and wrapping a metallic wrap around the edges of the cylinder to keep the 
treatment confined to the 7 mm circular adaptor’s treatment area. To prevent any 
long-term risks, proper procedure and the use of correctly mounted, well-polished 
metallic eye shields are critical for corneal protection. It’s important to remember 
that systems vary, and configurations can be tailored to the equipment in use and 
specific patient characteristics (skin texture, sun sensitivity, light-sensitizing drugs, 
and so on), with a thorough knowledge of the tissue effects at different settings/
parameters [1].
8.1 IPL care has a risk vs. benefit ratio
Gupta et al. proved that IPL therapy for evaporative DED is a safe treatment in a 
study [47].
IPL appears to be a reliable and successful therapy for patients with evapora-
tive DED, based on changes in quantitative clinical test results and subjective 
OSDI scoring evidence. The oil flow score and TBUT all increased significantly. 
There were no significant differences in intraocular pressure or acuity. There were 
no reports of ocular side effects. Some research found no adverse effects follow-
ing IPL therapy and a substantial increase in MGD symptoms. In Chinese MGD 
cases with darker skin types (Fitzpatrick skin types III-IV), IPL treatment has also 
been effective and safe. Rong et al. found that strong pulsed light directly exposed 
to the eyelids, together with meibomian gland expression, effectively treats 
MGD [48].
IPL, in combination with MGX, was a safe and successful treatment for MGD. 
However, we must remember that the light beam emitted will be directed on a par-
ticular region, selectively damaging specific targets in the area being treated (e.g., 
capillaries, brown spots, or tattoo color in the skin), causing them to be eliminated 
or the region to be replaced with new cells—depending on the preferred procedure. 
IPL’s effects can also be unwelcome, resulting in dangers like burns, blistering, and 
discomfort. Keloids and skin pigmentation are common severe symptoms. As a 
result, before proceeding with the procedure, the practitioner should advise the 
worried patients about the risks and benefits of IPL therapy. In meibomian gland 
dysfunction, intensive pulsed light therapy affects tear proteins, lipids, and inflam-
matory markers by controlling the amounts of total lipids, cholesterol, triglycerides, 
and phospholipids in the tear; IPL helps to alleviate the symptoms of DED. After 
IPL treatment, Ahmed et al. found substantial differences in tear protein con-
centrations and molecular weight [49]. The molecular weights of tear lysozyme, 
albumin, and lactoferrin were the most affected. The tears of MGD patients had 
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slightly smaller levels of anionic phosphatidylethanolamine, phosphatidylserine, 
and phosphatidylinositol on thin-layer chromatography, however typical levels of 
zwitterionic neutral phospholipid phosphatidylcholine. After IPL treatment, these 
anionic phospholipids demonstrated impressive improvement. IPL enhances tear 
protein and lipid content and structure. Several studies have found IPL therapy 
reduces interleukin-6, interleukin-17A, and prostaglandin E2 levels in DED patients’ 
tear fluid. Furthermore, they stated that a reduction in these inflammatory factors 
was related to decreased signs and symptoms. These decreases in inflammatory 
factors were linked to increases in corneal staining ratings, indicating that ocular 
surface epithelial damage had improved. According to some reports, changes in 
IL-6, IL-17A, and IL-1 levels were lowest one week after IPL, which was earlier than 
the appearance of clinical result peaks at one month. This means that increases in 
tear cytokine levels could be more sensitive indicators of IPL symptoms than clini-
cal signs. IPL has an impact on the MGD meibum.
IPL has been shown in several trials to help release clogged meibum by thermal 
pulsation treatment. MGD is a critical contributor to dry eye illness with Sjogren 
disease, according to Godin et al. study’s and should not be underestimated when 
evaluating care choices [50].
The meibum was able to clear its clogged ducts with the aid of thermal pulsa-
tion. Thermal pulsation is a treatment choice for patients with Sjogren’s disease who 
have dry eye and MGD symptoms, and it will increase meibum consistency directly. 
Another research by yin et al. found that after therapy, TBUT, OSDI, MG express-
ibility, meibum quality, and MG dropout increased. IPL therapy significantly 
increased MG microstructure indices such as meibum, MG Acinar Unit Density 
(AUD), MG Acinar Longest Diameter (ALD), and the positive rate of Inflammatory 
Cells (ICs) across glandular structures. These results indicate that IPL therapy 
helps DED patients with MGD symptoms. It also increases eyelid hygiene and 
related ocular-surface indices, MG function, and MG macrostructure. Moreover, in 
MGD cases, IPL therapy primarily enhanced MG microstructure and reduces MG 
inflammation. MGD causes a difference in meibum content and quantity, which 
contributes to evaporative dry eye and ocular surface damage, increasing dry eye 
symptoms in certain people, according to Chhadva et al. on the meibum of MGD 
patients [51]. These modifications can be systemically managed with IPL, reducing 
the patient’s difficulty [23, 31].
8.2 The advantages of IPL
Sufferers with refractory meibomian gland dysfunction are treated with intense 
pulsed light. Even more, research suggests that using strong pulsed light to treat 
MGD cases tends to alleviate dry eye symptoms. The aim of Arita et al. research.’s was 
to see whether strong pulsed light (IPL) combined with meibomian gland expres-
sion (MGX) could help with refractory meibomian gland dysfunction (MGD). Her 
findings indicated that combining IPL and MGX improved tear film homeostasis 
and alleviated ocular symptoms in cases with refractory MGD, making it a potential 
treatment option for this disorder. The meibomian gland activity was increased, 
the tear film was balanced, and ocular surface inflammation was reduced after 
IPL therapy. Meibum consistency, meibum expressibility, lid margin abnormality, 
ocular surface staining, tear film breakup period (TBUT), and the Ocular Surface 
Disease Index (OSDI) all improved significantly after IPL. Low meibum express-
ibility and a short TBUT were linked to a more significant improvement in the OSDI. 
Sufferers with refractory obstructive meibomian gland dysfunction responded well 
to IPL therapy combined with meibomian gland probing. Huang et al. discovered 
that, in comparison to IPL or Meibomian Gland Probing (MGP) alone, the mixture 
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MGP-IPL showed the most remarkable results in relieving all symptoms and signs 
and assisting patients in achieving long-term symptom relief [21, 52].
8.3 Evolution methods of IPL
The novel IPL/BBL from the high-intensity red (560–580 nm) to infrared 
(580–1200 nm) wavelengths of light may also improve blepharitis and DE by 
reducing Demodex and harmful bacteria [53]. This safe and effective protocol 
treats both the upper eyelid (more meibomian glands) and lower eyelids. It is 
now an off-label adaptation for ocular rosacea treatment (a form of MGD DED). 
Significant improvement of periocular symptomatology, MGD blepharitis 
symptoms, OSDI scores, and recurrence were observed with IPL/BBL after one 
year (Figure 4).
9. Discussion
Two types of IPL devices (E. Eye; E-SWIN, Paris, France, and Lumenis M22; Tel 
Aviv, Israel) were used in the studies. The E. Eye device produces a wavelength from 
580 to 1200 nm, whereas the Lumenis M22 produces a 400 to 1200 nm wavelength. 
The broader wavelength of Lumenis M22 can theoretically achieve a better bacte-
ricidal effect. The light between 400 and 700 nm (415 most effectively absorbed) 
for Propionibacterium acnes, 500 nm, probably induces photo-thermolysis of vessels 
and prevents the leakage of inflammatory cytokines into the ocular surface. The 
yellow wavelength of IPL can target the oxyhemoglobin in superficial skin vessels, 
which have light absorption peaks of 578 nm. The sustained reduction in telangi-
ectasia (decrease leakage of interleukins such as IL-17A and IL-6) was observed 
in patients with rosacea-related MGD after repeated IPL administration. On the 
contrary, the red-light spectrum (580–1200 nm) delivered by the E. Eye device has 
a more inadequate bactericidal effect. Still, it can potentially penetrate deeper into 
the skin and target the underlying sebaceous glands. And the use of the protective 
eye goggles is unclear or different between studies.
Figure 4. 
Comparison of methods of IPL with and without gel.
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The different wavelength is another confounding factor, although 500 to 
600 nm was used in most studies.
There are two intense pulsed light patterns: Optimal Pulse Technology (OPT) 
with three (3 weeks duration) consecutive treatments (10–14 J/cm2) is more 
effective in improving MG function in lower eyelids and partial tear film signs than 
Intense Regulated Pulsed Light (IRPL) with four treatments (9–13 J/cm2) on days 
(D)1, D15, D45, and D75 treatment. The method of light patterns used in each study 
causes a little disagreement.
Moreover, discrepancies between the ocular symptoms and signs of dry eye 
and the significant association of sleep disorders and ocular surface problems are 
common [54].
Besides, dry eye symptoms are more highly correlated with non-ocular condi-
tions (sometimes somatization) than dry eye signs. The questionnaire does not any 
focus on a specific drug history for insomnia or antidepressants with anticholinergic 
effects.
It is also not irrational to conclude that identical findings would have been 
observed in a particular demographic with various skin type dispensation [23]. 
Another restriction was the lack of a gold standard for diagnosing and using TBUT 
as the essential result measure. Many reports of DED use tear breakup time; as a 
result, measure, but this outcome measure is troublesome for many reasons [23]. 
This procedure has a mild specificity/sensitivity. The findings are depending on 
the amount of coloring (fluorescein) ingrained in the eye, and the method is highly 
subjective to the observer’s estimation. As a result, TBUT varies from one investiga-
tor to the next, even within the same investigator. While this averaging approach 
minimized TBUT measurement uncertainty, a more accurate and quantitative 
primary result indicator (e.g., NIBUT) may be a better option for investigation.
And finally, in the present pandemic, the eye route of infection must be con-
sidered so each sufferer should be treated as a potential coronavirus carrier. As 
a potentially beneficial method for treating and relieving the effects of DES and 
avoiding COVID-19, various compounds may be added into the food and then used 
as ready-made supplements. Polyunsaturated fatty acids had the most reported 
medicinal benefit, as they help alleviate the disease’s infectious aspect. Vitamins, 
omega acids, and other nutritional nutrients can be discussed with each person 
individually.
10. Conclusion
To summarize, IPL is an attractive alternative solution for sufferers with DED 
caused by MGD, and that the effect of IPL is real rather than a placebo effect.
11. Take-home messages
It is essential to address the following points:
1. As we know, the MGD is not yet an approved indication for IPL therapy by the 
United States Food and Drug Administration. Regarding the safety of IPL and 
reported adverse events (14% of patients: cheek swelling, conjunctival cyst, 
floaters, blistering, hair loss at brow and forehead, light sensitivity, and facial 
redness). The IPL treatment should adhere to lower eyelids for now and in the 
presence of ocular protection due to the report about uveitis and iris damage. 
Although adverse effects usually resolved without treatment within one week 
11
Intense Pulse Laser Therapy and Dry Eye Disease
DOI: http://dx.doi.org/10.5772/intechopen.99165
and iris damage has been reported during cosmetic IPL therapy on the upper 
eyelids by no ophthalmologic health care workers.
2. When we discuss about Intense Pulse Laser as a new treatment, confounding fac-
tors should be borne in mind: Age, baseline Ocular Surface Disease Index, MGD 
severity are potential factors that may influence the effects of IPL [55]. Some fac-
tors are difficult to control, such as patients’ lifestyle, hormone levels, mood, and 
environment, which may affect the therapeutic effect of IPL treatment as follows:
• Increased exercise and higher estrogen levels were also associated with 
improved tear quantity during the ovulation phase [56].
• The majority of the available studies on nutritional supplementation 
[57] for DED did not evaluate the micronutrient dietary intake nor their 
plasma level, representing the major limitation of the existing literature. 
However, Epitropoulos et al., Malhotra et al., and Oleñik et al. showed 
significant improvement in OSDI, TBUT, lid margin inflammation, and 
meibum expressibility placebo, using Eicosapentaenoic Acid (EPA) + 
Docosahexaenoic Acid (DHA) [57].
• On the other hand, sleep deprivation reduces androgen levels parasympa-
thetic activity. It makes high levels of stress hormones (norepinephrine and 
cortisol) and reduce tear secretion lacrimal system function that reversed 





CCES Change of Compound Eyelid Score
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FU Follow-up
ICs Inflammatory Cells
IHMGEC Immortalized Human MG Epithelial Cells
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Abbreviations Definitions
MGP Meibomian Gland Probing
MGX Meibomian Gland Expression
MGYSS Meibomian Gland Yielding Secretion Score
MMP Matrix Metalloproteinase
NIBUT Non-Invasive Breakup Time
OPT Optimal Pulse Technology
OSD Ocular Surface Disease
OSDI Ocular Surface Disease Index
RCTs Randomized Controlled Trials
SPEED Standard Patient Evaluation of Eye Dryness Questionnaire
SREBP-1 Sterol Regulatory Element-Binding Protein 1
TBUT Tear Breakup Time
TFLL Tear Film Lipid Layer
TFOD Tear Film-Oriented Diagnosis
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